The EMT6 orthotopic tumor model provided us with an opportunity to characterize the single-cell molecular responses to anti-PD-L1 ± anti-TGF-β treatment in a setting where anti-TGF-β addition overcomes resistance to anti-PD-L1 therapy. This evidence concerns the gene TGFB1 and neoplasm.